Efficacy and cardiovascular safety of daclizumab, mycophenolate mofetil, tacrolimus, and early steroid withdrawal in renal transplant recipients: A multicenter, prospective, pilot trial

Clinical Transplantation

Volumn 19, Issue 4, 2005, Pages 475-482

  Abramowicz, Daniel ^a   Vanrenterghem, Yves ^b   Squifflet, Jean Paul ^c   Kuypers, Dirk ^b   Mourad, Michel ^c   Meurisse, Michel ^d   Wissing, Martin ^a  

^a ERASME HOSPITAL   (Belgium)

^b UNIVERSITY OF LEUVEN   (Belgium)

^c UNIVERSITÉ CATHOLIQUE DE LOUVAIN   (Belgium)

^d CHU SART TILMAN   (Belgium)

Author keywords

Daclizumab; Mycophenolate mofetil; Renal transplant; Steroid free; Tacrolimus

Indexed keywords

CHOLESTEROL; COTRIMOXAZOLE; CREATININE; DACLIZUMAB; GANCICLOVIR; HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INSULIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; METHYLPREDNISOLONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; ORAL ANTIDIABETIC AGENT; PREDNISOLONE; TACROLIMUS; TRIACYLGLYCEROL;

ACUTE GRAFT REJECTION; ADULT; ANEMIA; ARTHRALGIA; ARTICLE; BELGIUM; BRONCHITIS; CARDIOVASCULAR RISK; CLINICAL TRIAL; COMMON COLD; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CREATININE CLEARANCE; CYTOMEGALOVIRUS INFECTION; DIABETES MELLITUS; DIARRHEA; DRUG BLOOD LEVEL; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG FEVER; DRUG SAFETY; DRUG WITHDRAWAL; DUODENUM ULCER; DYSLIPIDEMIA; EDEMA; ESOPHAGITIS; FEMALE; GRAFT SURVIVAL; HEART FAILURE; HERPES ZOSTER; HUMAN; HUMAN TISSUE; HYDROCELE; HYPERGLYCEMIA; HYPERPARATHYROIDISM; HYPERTENSION; KIDNEY ALLOGRAFT; KIDNEY BIOPSY; KIDNEY DYSFUNCTION; KIDNEY GRAFT REJECTION; LEUKOPENIA; LIPID ANALYSIS; LIVER DYSFUNCTION; MAJOR CLINICAL STUDY; MALE; MUCOCUTANEOUS CANDIDIASIS; MULTICENTER STUDY; OPEN STUDY; ORAL GLUCOSE TOLERANCE TEST; PILOT STUDY; PNEUMOCYSTIS PNEUMONIA; POSTOPERATIVE PERIOD; PRIORITY JOURNAL; RECIPIENT; SIDE EFFECT; STOMACH ULCER; THRUSH; URINARY TRACT INFECTION;

ANTIBODIES, MONOCLONAL; CARDIOVASCULAR SYSTEM; CHOLESTEROL; DRUG ADMINISTRATION SCHEDULE; FEMALE; GRAFT REJECTION; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; IMMUNOGLOBULIN G; IMMUNOSUPPRESSIVE AGENTS; KIDNEY TRANSPLANTATION; MALE; MIDDLE AGED; MYCOPHENOLIC ACID; PILOT PROJECTS; PREDNISOLONE; PROSPECTIVE STUDIES; STEROIDS; TACROLIMUS; TRIGLYCERIDES;

EID: 22244490359     PISSN: 09020063     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1399-0012.2005.00369.x     Document Type: Article

References (34)

1. Halloran P, Mathew T, Tomlanovich S, Groth C, Hooftman L, Barker C. Mycophenolate mofetil in renal allograft recipients: a pooled efficacy analysis of three randomized, double-blind, clinical studies in prevention of rejection. The International Mycophenolate Mofetil Renal Transplant Study Groups. Transplantation 1977: 63: 39.
2. Kahan BD. Drug therapy: cyclosporine. N Engl J Med 1989: 321: 1725.
3. Luke RG. Mechanisms of cyclosporine-induced hypertension. Am J Hypertens 1991: 4: 468.
4. Vincenti F, Jensik SC, Filo RS, Miller J, Pirsch J. A long-term comparison of tacrolimus (FK506) and cyclosporine in kidney transplantation: evidence for improved allograft survival at five years. Transplantation 2002: 73: 775.
5. First MR, Gerber DA, Hariharan S, Kaufman DB, Shapiro R. Posttransplant diabetes mellitus in kidney allograft recipients: incidence, risk factors, and management. Transplantation 2002: 73: 379.
6. Vanrenterghem Y, Lebranchu Y, Hene R, Oppenheimer F, Ekberg H. Double-blind comparison of two corticosteroid regimens plus mycophenolate mofetil and cyclosporine for prevention of acute renal allograft rejection. Transplantation 2000: 70: 1352.
7. Kasiske BL. Ischemic heart disease after renal transplantation. Kidney Int 2002: 61: 356.
8. Lebranchu Y, Aubert P, Bayle F et al. Could steroids be withdrawn in renal transplant patients sequentially treated with ATG, cyclosporine, and CellCept? One-year results of a double-blind, randomized, multicenter study comparing normal dose versus low-dose and withdrawal of steroids. M 55002 French Study Group. Transplant Proc 2000: 32: 396.
9. Steroid Withdrawal Study Group. Prednisone withdrawal in kidney transplant recipients on cyclosporine and mycophenolate mofetil - a prospective randomized study. Transplantation 1999: 68: 1865.
10. Webster AC, Playford EG, Higgins G, Chapman JR, Craig JC. Interleukin 2 receptor antagonists for renal transplant recipients: a meta-analysis of randomized trials. Transplantation 2004: 77: 166.
11. Lebranchu Y, Bridoux F, Buchler M et al. Immunoprophylaxis with basiliximab compared with antithymocyte globulin in renal transplant patients receiving MMF-containing triple therapy. Am J Transplant 2002: 2: 48.
12. Sollinger H, Kaplan B, Pescovitz MD et al. Basiliximab versus antithymocyte globulin for prevention of acute renal allograft rejection. Transplantation 2001: 72: 1915.
13. Ciancio G, Burke GW, Suzart K et al. Daclizumab induction, tacrolimus, mycophenolate mofetil and steroids as an immunosuppression regimen for primary kidney transplant recipients. Transplantation 2002: 73: 1100.
14. Ahsan N, Holman MJ, Jarowenko MV, Razzaque MS, Yang HC. Limited dose monoclonal IL-2R antibody induction protocol after primary kidney transplantation. Am J Transplant 2002: 2: 568.
15. Lawen JG, Davies EA, Mourad G et al. Randomized double-blind study of immunoprophylaxis with basiliximab, a chimeric anti-interleukin-2 receptor monoclonal antibody, in combination with mycophenolate mofetil-containing triple therapy in renal transplantation. Transplantation 2003: 75: 37.
16. Vincenti F, Monaco A, Grinyo J, Kinkhabwala M, Roza A. Multicenter randomized prospective trial of steroid withdrawal in renal transplant recipients receiving basiliximab, cyclosporine microemulsion and mycophenolate mofetil. Am J Transplant 2003: 3: 306.
17. Cole E, Landsberg D, Russell D et al. A pilot study of steroid-free immunosuppression in the prevention of acute rejection in renal allograft recipients. Transplantation 2001: 72: 845.
18. Vincenti F, Ramos E, Brattstrom C et al. Multicenter trial exploring calcineurin inhibitors avoidance in renal transplantation. Transplantation 2001: 71: 1282.
19. Tran HT, Acharya MK, McKay DB et al. Avoidance of cyclosporine in renal transplantation: effects of daclizumab, mycophenolate mofetil, and steroids. J Am Soc Nephrol 2000: 11: 1903.
20. Racusen LC, Solez K, Colvin RB et al. The Banff 97 working classification of renal allograft pathology. Kidney Int 1999: 55: 713.
21. Kuypers DR, Vanrenterghem Y. Prophylaxis of cytomegalovirus infection in renal transplantation. Nephrol Dial Transplant 1998: 13: 3012.
22. Vincenti F, Kirkman R, Light S et al. Interleukin-2-receptor blockade with daclizumab to prevent acute rejection in renal transplantation. N Engl J Med 1998: 338: 161.
23. Ojo AO, Meier-Kriesche HU, Hanson JA et al. Mycophenolate mofetil reduces late renal allograft loss independent of acute rejection. Transplantation 2000: 69: 2405.
24. Pescovitz MD, Bumgardner G, Gaston RS et al. Pharmacokinetics of daclizumab and mycophenolate mofetil with cyclosporine and steroids in renal transplantation. Clin Transplant 2003: 17: 511.
25. Ter Meulen CG, Van Riemsdijk I, Hene RJ et al. Steroid-withdrawal at 3 days after renal transplantation with anti-IL-2 receptor alpha therapy: a prospective, randomized, multicenter study. Am J Transplant 2004: 4: 803.
26. Pirsch JD, Miller J, Deierhoi MH, Vincenti F, Filo RS. A comparison of tacrolimus (FK506) and cyclosporine for immunosuppression after cadaveric renal transplantation. Transplantation 1997: 63: 977.
27. Mayer AD, Dmitrewski J, Squifflet JP et al. Multicenter randomized trial comparing tacrolimus (FK506) and cyclosporine in the prevention of renal allograft rejection. Transplantation 1997: 64: 436.
28. Gonwa T, Mendez R, Yang HC et al. Randomized trial of tacrolimus in combination with sirolimus or mycophenolate mofetil in kidney transplantation: results at 6 months. Transplantation 2003: 75: 1213.
29. Margreiter R. European Tacrolimus vs Ciclosporin Microemulsion Renal Transplantation Study Group. Efficacy and safety of tacrolimus compared with ciclosporin microemulsion in renal transplantation: a randomised multicentre study. Lancet 2002: 359: 741.
30. Kasiske B, Cosio FG, Beto J et al. Clinical practice guidelines for managing dyslipidemias in kidney transplant patients: a report from the Managing Dyslipidemias in Chronic Kidney Disease Work Group of the National Kidney Foundation Kidney Disease Outcomes Quality Initiative. Am J Transplant 2004: 4(Suppl 7): 13.
31. Heisel O, Heisel R, Balshaw R, Keown P. New onset diabetes mellitus in patients receiving calcineurin inhibitors: a systematic review and meta-analysis. Am J Transplant 2004: 4: 583.
32. Hjelmesaeth J, Hagen M, Hartmann A, Midtvedt K, Egeland T, Jenssen T. The impact of impaired insulin release and insulin resistance on glucose intolerance after renal transplantation. Clin Transplant 2002: 16: 389.
33. Maes BD, Kuypers D, Messiaen T et al. Posttransplantation diabetes mellitus in FK-506-treated renal transplant recipients: analysis of incidence and risk factors. Transplantation 2001: 72: 1655.
34. Kasiske BL, Snyder JJ, Gilbertson D, Matas AJ. Diabetes mellitus after kidney transplantation in the United States. Am J Transplant 2003: 3: 178.